Pharma BD Deal Intelligence

Sanofi SA / Provention Bio Inc.

2023 · Acquisition/Merger · $2.9B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Sanofi acquired Provention Bio for $25 per share (approximately $2.9 billion total), gaining access to teplizumab (Tzield), the first FDA-approved therapy to delay the onset of type 1 diabetes.

Key facts

Announced Feb 17, 2023
Closed Apr 27, 2023
Deal value $2.9B
Deal type Acquisition/Merger
Therapeutic area Immunology, Metabolic
Indications Type 1 Diabetes
Key assets Teplizumab (Tzield)
Mechanism Anti-CD3 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals